CG Oncology, Inc. (CGON)

CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $3.32 billion. The enterprise value is $2.67 billion.

Market Cap	3.32B
Enterprise Value	2.67B

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025, before market open.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 76.25 million shares outstanding. The number of shares has increased by 376.91% in one year.

Current Share Class	76.25M
Shares Outstanding	76.25M
Shares Change (YoY)	+376.91%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	0.86%
Owned by Institutions (%)	98.52%
Float	61.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6,048.61
Forward PS	n/a
PB Ratio	4.97
P/TBV Ratio	4.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4,850.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 22.15, with a Debt / Equity ratio of 0.00.

Current Ratio	22.15
Quick Ratio	21.78
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-23.44%
Revenue Per Employee	$4,876
Profits Per Employee	-$1.13M
Employee Count	113
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.65% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+16.65%
50-Day Moving Average	36.55
200-Day Moving Average	28.57
Relative Strength Index (RSI)	62.15
Average Volume (20 Days)	953,049

Short Selling Information

The latest short interest is 12.22 million, so 16.03% of the outstanding shares have been sold short.

Short Interest	12.22M
Short Previous Month	11.99M
Short % of Shares Out	16.03%
Short % of Float	20.03%
Short Ratio (days to cover)	11.26

Income Statement

In the last 12 months, CG Oncology had revenue of $551,000 and -$128.08 million in losses. Loss per share was -$1.77.

Revenue	551,000
Gross Profit	-84.18M
Operating Income	-157.29M
Pretax Income	-128.08M
Net Income	-128.08M
EBITDA	-157.09M
EBIT	-157.29M
Loss Per Share	-$1.77

Balance Sheet

The company has $661.05 million in cash and $994,000 in debt, giving a net cash position of $660.06 million or $8.66 per share.

Cash & Cash Equivalents	661.05M
Total Debt	994,000
Net Cash	660.06M
Net Cash Per Share	$8.66
Equity (Book Value)	670.36M
Book Value Per Share	8.79
Working Capital	642.65M

Cash Flow

In the last 12 months, operating cash flow was -$93.82 million and capital expenditures -$238,000, giving a free cash flow of -$94.06 million.

Operating Cash Flow	-93.82M
Capital Expenditures	-238,000
Free Cash Flow	-94.06M
FCF Per Share	-$1.23

Margins

Gross Margin	n/a
Operating Margin	-28,546.10%
Pretax Margin	-23,245.19%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-376.91%
Shareholder Yield	-376.91%
Earnings Yield	-3.84%
FCF Yield	-2.82%

Analyst Forecast

The average price target for CG Oncology is $67.45, which is 55.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$67.45
Price Target Difference	55.02%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	269.49%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 41.68 and a Piotroski F-Score of 1.

Altman Z-Score	41.68
Piotroski F-Score	1